annual FCF:
$239.25M+$177.40M(+286.79%)Summary
- As of today (July 1, 2025), CPRX annual free cash flow is $239.25 million, with the most recent change of +$177.40 million (+286.79%) on December 31, 2024.
- During the last 3 years, CPRX annual FCF has risen by +$179.90 million (+303.11%).
- CPRX annual FCF is now at all-time high.
Performance
CPRX Free cash flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly FCF:
$60.04M-$10.75M(-15.18%)Summary
- As of today (July 1, 2025), CPRX quarterly free cash flow is $60.04 million, with the most recent change of -$10.75 million (-15.18%) on March 31, 2025.
- Over the past year, CPRX quarterly FCF has increased by +$28.32 million (+89.25%).
- CPRX quarterly FCF is now -17.31% below its all-time high of $72.61 million, reached on September 30, 2024.
Performance
CPRX quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM FCF:
$267.57M+$28.32M(+11.84%)Summary
- As of today (July 1, 2025), CPRX TTM free cash flow is $267.57 million, with the most recent change of +$28.32 million (+11.84%) on March 31, 2025.
- Over the past year, CPRX TTM FCF has increased by +$185.98 million (+227.96%).
- CPRX TTM FCF is now at all-time high.
Performance
CPRX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Free cash flow Formula
FCF = Cash From Operations − CAPEX
CPRX Free cash flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +286.8% | +89.3% | +228.0% |
| 3 y3 years | +303.1% | +608.2% | +312.1% |
| 5 y5 years | +591.6% | +732.4% | +445.7% |
CPRX Free cash flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +303.1% | -17.3% | +275.4% | at high | +450.5% |
| 5 y | 5-year | at high | +591.6% | -17.3% | +275.4% | at high | +557.2% |
| alltime | all time | at high | +1011.8% | -17.3% | +275.4% | at high | +1049.5% |
CPRX Free cash flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $60.04M(-15.2%) | $267.57M(+11.8%) |
| Dec 2024 | $239.25M(+286.8%) | $70.79M(-2.5%) | $239.25M(+7.9%) |
| Sep 2024 | - | $72.61M(+13.2%) | $221.79M(+92.9%) |
| Jun 2024 | - | $64.13M(+102.1%) | $114.96M(+40.9%) |
| Mar 2024 | - | $31.73M(-40.5%) | $81.59M(+31.9%) |
| Dec 2023 | $61.86M(-46.7%) | $53.33M(-255.8%) | $61.86M(+27.3%) |
| Sep 2023 | - | -$34.22M(-211.3%) | $48.60M(-60.8%) |
| Jun 2023 | - | $30.75M(+156.4%) | $124.13M(+3.8%) |
| Mar 2023 | - | $12.00M(-70.1%) | $119.54M(+3.0%) |
| Dec 2022 | $116.02M(+95.5%) | $40.08M(-3.0%) | $116.02M(+22.0%) |
| Sep 2022 | - | $41.30M(+57.9%) | $95.08M(+26.1%) |
| Jun 2022 | - | $26.16M(+208.6%) | $75.41M(+16.2%) |
| Mar 2022 | - | $8.48M(-55.7%) | $64.93M(+9.4%) |
| Dec 2021 | $59.35M(+31.8%) | $19.14M(-11.6%) | $59.35M(+11.3%) |
| Sep 2021 | - | $21.64M(+38.1%) | $53.32M(+23.7%) |
| Jun 2021 | - | $15.67M(+439.9%) | $43.12M(+5.9%) |
| Mar 2021 | - | $2.90M(-77.8%) | $40.71M(-9.6%) |
| Dec 2020 | $45.02M(+30.2%) | $13.11M(+14.6%) | $45.02M(+1.8%) |
| Sep 2020 | - | $11.44M(-13.8%) | $44.21M(-9.8%) |
| Jun 2020 | - | $13.27M(+83.9%) | $49.03M(-1.6%) |
| Mar 2020 | - | $7.21M(-41.3%) | $49.83M(+44.0%) |
| Dec 2019 | $34.59M(-231.8%) | $12.29M(-24.4%) | $34.59M(+149.0%) |
| Sep 2019 | - | $16.26M(+15.7%) | $13.89M(-248.6%) |
| Jun 2019 | - | $14.06M(-275.3%) | -$9.35M(-66.8%) |
| Mar 2019 | - | -$8.02M(-4.6%) | -$28.18M(+7.4%) |
| Dec 2018 | -$26.24M(+90.9%) | -$8.41M(+20.5%) | -$26.24M(+20.0%) |
| Sep 2018 | - | -$6.98M(+46.1%) | -$21.86M(+24.8%) |
| Jun 2018 | - | -$4.77M(-21.5%) | -$17.52M(+9.9%) |
| Mar 2018 | - | -$6.08M(+50.9%) | -$15.95M(+16.0%) |
| Dec 2017 | -$13.74M(-23.9%) | -$4.03M(+53.1%) | -$13.74M(-2.8%) |
| Sep 2017 | - | -$2.63M(-17.8%) | -$14.13M(-4.4%) |
| Jun 2017 | - | -$3.20M(-17.5%) | -$14.78M(-7.7%) |
| Mar 2017 | - | -$3.88M(-12.2%) | -$16.01M(-11.4%) |
| Dec 2016 | -$18.06M(+0.1%) | -$4.42M(+34.8%) | -$18.06M(-1.2%) |
| Sep 2016 | - | -$3.28M(-26.0%) | -$18.27M(-10.2%) |
| Jun 2016 | - | -$4.43M(-25.3%) | -$20.35M(+0.9%) |
| Mar 2016 | - | -$5.93M(+28.0%) | -$20.17M(+11.8%) |
| Dec 2015 | -$18.04M | -$4.63M(-13.6%) | -$18.04M(+3.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | -$5.36M(+26.2%) | -$17.40M(+11.5%) |
| Jun 2015 | - | -$4.25M(+11.7%) | -$15.61M(+8.7%) |
| Mar 2015 | - | -$3.80M(-4.8%) | -$14.36M(+10.5%) |
| Dec 2014 | -$13.00M(+31.5%) | -$3.99M(+12.0%) | -$13.00M(-1.0%) |
| Sep 2014 | - | -$3.57M(+19.0%) | -$13.14M(+16.7%) |
| Jun 2014 | - | -$3.00M(+22.7%) | -$11.25M(+11.8%) |
| Mar 2014 | - | -$2.44M(-40.9%) | -$10.07M(+1.9%) |
| Dec 2013 | -$9.89M(+90.4%) | -$4.13M(+145.3%) | -$9.89M(+33.7%) |
| Sep 2013 | - | -$1.68M(-7.1%) | -$7.39M(+8.6%) |
| Jun 2013 | - | -$1.81M(-19.8%) | -$6.81M(+10.8%) |
| Mar 2013 | - | -$2.26M(+37.8%) | -$6.15M(+18.3%) |
| Dec 2012 | -$5.19M(+4.1%) | -$1.64M(+48.9%) | -$5.19M(+4.0%) |
| Sep 2012 | - | -$1.10M(-4.0%) | -$4.99M(-2.9%) |
| Jun 2012 | - | -$1.15M(-12.2%) | -$5.15M(-5.8%) |
| Mar 2012 | - | -$1.31M(-9.3%) | -$5.46M(+9.5%) |
| Dec 2011 | -$4.99M(+32.7%) | -$1.44M(+15.0%) | -$4.99M(+15.5%) |
| Sep 2011 | - | -$1.25M(-14.5%) | -$4.32M(+11.2%) |
| Jun 2011 | - | -$1.46M(+76.3%) | -$3.88M(+8.8%) |
| Mar 2011 | - | -$831.10K(+8.0%) | -$3.57M(-5.1%) |
| Dec 2010 | -$3.76M(-51.1%) | -$769.20K(-5.9%) | -$3.76M(-1.6%) |
| Sep 2010 | - | -$817.30K(-28.9%) | -$3.82M(-12.3%) |
| Jun 2010 | - | -$1.15M(+12.5%) | -$4.35M(-25.8%) |
| Mar 2010 | - | -$1.02M(+23.2%) | -$5.87M(-23.6%) |
| Dec 2009 | -$7.69M(-7.0%) | -$828.90K(-38.7%) | -$7.68M(-21.2%) |
| Sep 2009 | - | -$1.35M(-49.2%) | -$9.75M(-10.7%) |
| Jun 2009 | - | -$2.66M(-6.1%) | -$10.92M(+10.6%) |
| Mar 2009 | - | -$2.84M(-2.2%) | -$9.87M(+19.5%) |
| Dec 2008 | -$8.26M(+84.0%) | -$2.90M(+15.1%) | -$8.26M(+31.1%) |
| Sep 2008 | - | -$2.52M(+56.0%) | -$6.30M(+40.2%) |
| Jun 2008 | - | -$1.62M(+31.8%) | -$4.50M(+3.5%) |
| Mar 2008 | - | -$1.23M(+30.0%) | -$4.35M(-3.2%) |
| Dec 2007 | -$4.49M(+274.4%) | -$942.30K(+32.0%) | -$4.49M(+26.6%) |
| Sep 2007 | - | -$714.00K(-51.3%) | -$3.55M(+25.2%) |
| Jun 2007 | - | -$1.46M(+6.9%) | -$2.83M(+106.9%) |
| Mar 2007 | - | -$1.37M | -$1.37M |
| Dec 2006 | -$1.20M(+161.2%) | - | - |
| Dec 2005 | -$459.30K(+97.6%) | - | - |
| Dec 2004 | -$232.40K | - | - |
FAQ
- What is Catalyst Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual FCF year-on-year change?
- What is Catalyst Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly FCF year-on-year change?
- What is Catalyst Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals TTM FCF year-on-year change?
What is Catalyst Pharmaceuticals annual free cash flow?
The current annual FCF of CPRX is $239.25M
What is the all time high annual FCF for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual free cash flow is $239.25M
What is Catalyst Pharmaceuticals annual FCF year-on-year change?
Over the past year, CPRX annual free cash flow has changed by +$177.40M (+286.79%)
What is Catalyst Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of CPRX is $60.04M
What is the all time high quarterly FCF for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly free cash flow is $72.61M
What is Catalyst Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, CPRX quarterly free cash flow has changed by +$28.32M (+89.25%)
What is Catalyst Pharmaceuticals TTM free cash flow?
The current TTM FCF of CPRX is $267.57M
What is the all time high TTM FCF for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high TTM free cash flow is $267.57M
What is Catalyst Pharmaceuticals TTM FCF year-on-year change?
Over the past year, CPRX TTM free cash flow has changed by +$185.98M (+227.96%)